Managers / Q1 2023 · view latest →
Artia Global Partners LP
CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384
Summary
Artia Global Partners LP reported $271M in U.S.-listed holdings across 36 positions for Q1 2023.
Its largest position, NVO, represents 18.9% of the portfolio.
Compared with Q4 2022, the fund opened 14 new positions and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 56.3% · $152M
- ADR · 29.0% · $78M
- Other · 14.7% · $40M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SAREPTA THERAPEUTICS INC | NEW | +60.0K | 60.0K | +$8M | $8M |
| NOVO-NORDISK A S | NEW | +50.0K | 50.0K | +$8M | $8M |
| KARUNA THERAPEUTICS INC | NEW | +30.0K | 30.0K | +$5M | $5M |
| RETAEURREATA PHARMACEUTICALS INC | NEW | +40.0K | 40.0K | +$4M | $4M |
| CYMABAY THERAPEUTICS INC | NEW | +169.3K | 169.3K | +$1M | $1M |
| CHARLES RIV LABS INTL INC | NEW | +6.9K | 6.9K | +$1M | $1M |
| ROIVANT SCIENCES LTD | NEW | +157.8K | 157.8K | +$1M | $1M |
| FGENEURFIBROGEN INC | NEW | +51.8K | 51.8K | +$966,495 | $966,495 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $499M | 50 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $706M | 55 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $631M | 51 | Nov 14, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2025 | $416M | 37 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $395M | 38 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $280M | 37 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $367M | 45 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $517M | 46 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $498M | 49 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $344M | 31 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $241M | 27 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $290M | 34 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $271M | 36 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $262M | 25 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.